Inozyme Pharma Archives

Media Coverage
September 23, 2022

Building a Pipeline of Therapies to Treat Rare Mineralization Disorders

Global Genes Podcast

GLOBAL GENES PODCAST: Global Genes spoke to spoke to Axel Bolte, co-founder and CEO of Inozyme, about ENPP1 deficiency, its lead experimental therapy to treat the condition, and its work with Rady Children’s Institute for Genomic Medicine to improve the diagnosis of newborns.

Media Coverage
August 25, 2022

BeginNGS Program Seeks to Improve Pediatric Rare Disease Dx, Treatment via Rapid NGS, Data Curation

GenomeWeb

GENOMEWEB: In a paper published this week in the American Journal of Human Genetics, collaborators led by the Rady Children's Institute for Genomic Medicine (RCIGM) formally spelled out plans to improve detection and treatment of rare hereditary pediatric diseases through rapid whole-genome sequencing (rWGS).

Media Coverage
July 25, 2022

The earlier the better: New consortium leverages infant screening to accelerate treatment

PharmaVoice

PHARMAVOICE: Newborn screening is gaining prominence across the biopharma and healthcare industries amid efforts to detect and treat disease as early as possible.

Media Coverage
June 16, 2022

Rady Children’s Institute for Genomic Medicine Partners With Inozyme Pharma on NGS Newborn Screening

GenomeWeb

Press Releases
June 14, 2022

News Center Archives

About us

Tag: Inozyme Pharma

Building a Pipeline of Therapies to Treat Rare Mineralization Disorders

BeginNGS Program Seeks to Improve Pediatric Rare Disease Dx, Treatment via Rapid NGS, Data Curation

The earlier the better: New consortium leverages infant screening to accelerate treatment

Rady Children’s Institute for Genomic Medicine Partners With Inozyme Pharma on NGS Newborn Screening

RCIGM Launches Program to Advance Newborn Screening for Treatable Genetic Diseases

Partner With Us

Order a Test

About Us

STAY UP TO DATE

Follow Us

Contact Us About BeginNGS